<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Tasfaout H</submitter><funding>Wellstone Center at the University of Washington</funding><funding>University of Washington Center for Translational Muscle Research</funding><funding>Diabetes Research Center</funding><funding>Association Française contre les Myopathies</funding><funding>US Department of Defense</funding><funding>National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health</funding><funding>Muscular Dystrophy Association</funding><pagination>e189075</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12321383</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>135(15)</volume><pubmed_abstract>Gene replacement therapies mediated by adeno-associated viral (AAV) vectors represent a promising approach for treating genetic diseases. However, their modest packaging capacity (~4.7 kb) remains an important constraint and significantly limits their application for genetic disorders involving large genes. A prominent example is Duchenne muscular dystrophy (DMD), whose protein product dystrophin is generated from a 11.2 kb segment of the DMD mRNA. Here, we explored methods that enable efficient expression of full-length dystrophin via triple AAV codelivery. This method exploits the protein trans-splicing mechanism mediated by split inteins. We identified a combination of efficient and specific split intein pairs that enabled the reconstitution of full-length dystrophin from 3 dystrophin f</pubmed_abstract><journal>The Journal of clinical investigation</journal><pubmed_title>Expression of full-length dystrophin reverses muscular dystrophy defects in young and old mdx4cv mice.</pubmed_title><pmcid>PMC12321383</pmcid><funding_grant_id>P30AR074990</funding_grant_id><funding_grant_id>R01HL128368</funding_grant_id><funding_grant_id>P30 DK017047</funding_grant_id><funding_grant_id>P50 AR065139</funding_grant_id><funding_grant_id>1060372</funding_grant_id><funding_grant_id>24777</funding_grant_id><funding_grant_id>MD220097</funding_grant_id><pubmed_authors>Tasfaout H</pubmed_authors><pubmed_authors>Tian R</pubmed_authors><pubmed_authors>Regnier M</pubmed_authors><pubmed_authors>McMillen TS</pubmed_authors><pubmed_authors>Chamberlain JS</pubmed_authors><pubmed_authors>Halbert CL</pubmed_authors><pubmed_authors>Reyes TR</pubmed_authors></additional><is_claimable>false</is_claimable><name>Expression of full-length dystrophin reverses muscular dystrophy defects in young and old mdx4cv mice.</name><description>Gene replacement therapies mediated by adeno-associated viral (AAV) vectors represent a promising approach for treating genetic diseases. However, their modest packaging capacity (~4.7 kb) remains an important constraint and significantly limits their application for genetic disorders involving large genes. A prominent example is Duchenne muscular dystrophy (DMD), whose protein product dystrophin is generated from a 11.2 kb segment of the DMD mRNA. Here, we explored methods that enable efficient expression of full-length dystrophin via triple AAV codelivery. This method exploits the protein trans-splicing mechanism mediated by split inteins. We identified a combination of efficient and specific split intein pairs that enabled the reconstitution of full-length dystrophin from 3 dystrophin f</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Aug</publication><modification>2026-03-31T11:30:53.763Z</modification><creation>2025-08-31T03:08:28.761Z</creation></dates><accession>S-EPMC12321383</accession><cross_references><pubmed>40493400</pubmed><doi>10.1172/JCI189075</doi></cross_references></HashMap>